Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer

Philip E. Castle, Walter K. Kinney, Xiaonan (Nan) Xue, Li C. Cheung, Julia C. Gage, Fang Hui Zhao, Barbara Fetterman, Nancy E. Poitras, Thomas S. Lorey, Nicolas Wentzensen, Hormuzd A. Katki, Mark Schiffman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Current U.S. cervical cancer screening and management guidelines do not consider previous screening history, because data on multiple-round human papillomavirus (HPV) and cytology “co-testing” have been unavailable. Objective: To measure cervical cancer risk in routine practice after successive negative screening co-tests at 3-year intervals. Design: Observational cohort study. Setting: Integrated health care system (Kaiser Permanente Northern California, Oakland, California). Patients: 990 013 women who had 1 or more co-tests from 2003 to 2014. Measurements: 3- and 5-year cumulative detection of (risk for) cervical intraepithelial neoplasia grade 3, adenocarcinoma in situ, and cervical cancer (≥CIN3) in women with different numbers of negative co-tests, overall and within subgroups defined by previous co-test results or baseline age. Results: Five-year ≥CIN3 risks decreased after each successive negative co-test screening round (0.098%, 0.052%, and 0.035%). Five-year ≥CIN3 risks for an HPV-negative co-test, regardless of

the cytology result, nearly matched the performance (reassurance) of a negative co-test for each successive round of screening (0.114%, 0.061%, and 0.041%). By comparison, ≥CIN3 risks for the cytology-negative co-test, regardless of the HPV result, also decreased with each successive round, but 3-year risks were as high as 5-year risks after an HPV-negative co-test (0.199%, 0.065%, and 0.043%). No interval cervical cancer cases were diagnosed after the second negative co-test. Independently, ≥CIN3 risks decreased with age. Length of previous screening interval did not influence future ≥CIN3 risks. Limitation: Interval-censored observational data. Conclusion: After 1 or more negative cervical co-tests (or HPV tests), longer screening intervals (every 5 years or more) might be feasible and safe.

Original languageEnglish (US)
Pages (from-to)20-29
Number of pages10
JournalAnnals of Internal Medicine
Volume168
Issue number1
DOIs
StatePublished - Jan 2 2018

Fingerprint

Uterine Cervical Neoplasms
Cell Biology
Safety
Integrated Delivery of Health Care
Cervical Intraepithelial Neoplasia
Early Detection of Cancer
Observational Studies
Cohort Studies
History
Guidelines

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer. / Castle, Philip E.; Kinney, Walter K.; Xue, Xiaonan (Nan); Cheung, Li C.; Gage, Julia C.; Zhao, Fang Hui; Fetterman, Barbara; Poitras, Nancy E.; Lorey, Thomas S.; Wentzensen, Nicolas; Katki, Hormuzd A.; Schiffman, Mark.

In: Annals of Internal Medicine, Vol. 168, No. 1, 02.01.2018, p. 20-29.

Research output: Contribution to journalArticle

Castle, PE, Kinney, WK, Xue, XN, Cheung, LC, Gage, JC, Zhao, FH, Fetterman, B, Poitras, NE, Lorey, TS, Wentzensen, N, Katki, HA & Schiffman, M 2018, 'Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer', Annals of Internal Medicine, vol. 168, no. 1, pp. 20-29. https://doi.org/10.7326/M17-1609
Castle, Philip E. ; Kinney, Walter K. ; Xue, Xiaonan (Nan) ; Cheung, Li C. ; Gage, Julia C. ; Zhao, Fang Hui ; Fetterman, Barbara ; Poitras, Nancy E. ; Lorey, Thomas S. ; Wentzensen, Nicolas ; Katki, Hormuzd A. ; Schiffman, Mark. / Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer. In: Annals of Internal Medicine. 2018 ; Vol. 168, No. 1. pp. 20-29.
@article{3c8ebab3ebb54df08c3a499a0ad2bb11,
title = "Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer",
abstract = "Background: Current U.S. cervical cancer screening and management guidelines do not consider previous screening history, because data on multiple-round human papillomavirus (HPV) and cytology “co-testing” have been unavailable. Objective: To measure cervical cancer risk in routine practice after successive negative screening co-tests at 3-year intervals. Design: Observational cohort study. Setting: Integrated health care system (Kaiser Permanente Northern California, Oakland, California). Patients: 990 013 women who had 1 or more co-tests from 2003 to 2014. Measurements: 3- and 5-year cumulative detection of (risk for) cervical intraepithelial neoplasia grade 3, adenocarcinoma in situ, and cervical cancer (≥CIN3) in women with different numbers of negative co-tests, overall and within subgroups defined by previous co-test results or baseline age. Results: Five-year ≥CIN3 risks decreased after each successive negative co-test screening round (0.098{\%}, 0.052{\%}, and 0.035{\%}). Five-year ≥CIN3 risks for an HPV-negative co-test, regardless ofthe cytology result, nearly matched the performance (reassurance) of a negative co-test for each successive round of screening (0.114{\%}, 0.061{\%}, and 0.041{\%}). By comparison, ≥CIN3 risks for the cytology-negative co-test, regardless of the HPV result, also decreased with each successive round, but 3-year risks were as high as 5-year risks after an HPV-negative co-test (0.199{\%}, 0.065{\%}, and 0.043{\%}). No interval cervical cancer cases were diagnosed after the second negative co-test. Independently, ≥CIN3 risks decreased with age. Length of previous screening interval did not influence future ≥CIN3 risks. Limitation: Interval-censored observational data. Conclusion: After 1 or more negative cervical co-tests (or HPV tests), longer screening intervals (every 5 years or more) might be feasible and safe.",
author = "Castle, {Philip E.} and Kinney, {Walter K.} and Xue, {Xiaonan (Nan)} and Cheung, {Li C.} and Gage, {Julia C.} and Zhao, {Fang Hui} and Barbara Fetterman and Poitras, {Nancy E.} and Lorey, {Thomas S.} and Nicolas Wentzensen and Katki, {Hormuzd A.} and Mark Schiffman",
year = "2018",
month = "1",
day = "2",
doi = "10.7326/M17-1609",
language = "English (US)",
volume = "168",
pages = "20--29",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer

AU - Castle, Philip E.

AU - Kinney, Walter K.

AU - Xue, Xiaonan (Nan)

AU - Cheung, Li C.

AU - Gage, Julia C.

AU - Zhao, Fang Hui

AU - Fetterman, Barbara

AU - Poitras, Nancy E.

AU - Lorey, Thomas S.

AU - Wentzensen, Nicolas

AU - Katki, Hormuzd A.

AU - Schiffman, Mark

PY - 2018/1/2

Y1 - 2018/1/2

N2 - Background: Current U.S. cervical cancer screening and management guidelines do not consider previous screening history, because data on multiple-round human papillomavirus (HPV) and cytology “co-testing” have been unavailable. Objective: To measure cervical cancer risk in routine practice after successive negative screening co-tests at 3-year intervals. Design: Observational cohort study. Setting: Integrated health care system (Kaiser Permanente Northern California, Oakland, California). Patients: 990 013 women who had 1 or more co-tests from 2003 to 2014. Measurements: 3- and 5-year cumulative detection of (risk for) cervical intraepithelial neoplasia grade 3, adenocarcinoma in situ, and cervical cancer (≥CIN3) in women with different numbers of negative co-tests, overall and within subgroups defined by previous co-test results or baseline age. Results: Five-year ≥CIN3 risks decreased after each successive negative co-test screening round (0.098%, 0.052%, and 0.035%). Five-year ≥CIN3 risks for an HPV-negative co-test, regardless ofthe cytology result, nearly matched the performance (reassurance) of a negative co-test for each successive round of screening (0.114%, 0.061%, and 0.041%). By comparison, ≥CIN3 risks for the cytology-negative co-test, regardless of the HPV result, also decreased with each successive round, but 3-year risks were as high as 5-year risks after an HPV-negative co-test (0.199%, 0.065%, and 0.043%). No interval cervical cancer cases were diagnosed after the second negative co-test. Independently, ≥CIN3 risks decreased with age. Length of previous screening interval did not influence future ≥CIN3 risks. Limitation: Interval-censored observational data. Conclusion: After 1 or more negative cervical co-tests (or HPV tests), longer screening intervals (every 5 years or more) might be feasible and safe.

AB - Background: Current U.S. cervical cancer screening and management guidelines do not consider previous screening history, because data on multiple-round human papillomavirus (HPV) and cytology “co-testing” have been unavailable. Objective: To measure cervical cancer risk in routine practice after successive negative screening co-tests at 3-year intervals. Design: Observational cohort study. Setting: Integrated health care system (Kaiser Permanente Northern California, Oakland, California). Patients: 990 013 women who had 1 or more co-tests from 2003 to 2014. Measurements: 3- and 5-year cumulative detection of (risk for) cervical intraepithelial neoplasia grade 3, adenocarcinoma in situ, and cervical cancer (≥CIN3) in women with different numbers of negative co-tests, overall and within subgroups defined by previous co-test results or baseline age. Results: Five-year ≥CIN3 risks decreased after each successive negative co-test screening round (0.098%, 0.052%, and 0.035%). Five-year ≥CIN3 risks for an HPV-negative co-test, regardless ofthe cytology result, nearly matched the performance (reassurance) of a negative co-test for each successive round of screening (0.114%, 0.061%, and 0.041%). By comparison, ≥CIN3 risks for the cytology-negative co-test, regardless of the HPV result, also decreased with each successive round, but 3-year risks were as high as 5-year risks after an HPV-negative co-test (0.199%, 0.065%, and 0.043%). No interval cervical cancer cases were diagnosed after the second negative co-test. Independently, ≥CIN3 risks decreased with age. Length of previous screening interval did not influence future ≥CIN3 risks. Limitation: Interval-censored observational data. Conclusion: After 1 or more negative cervical co-tests (or HPV tests), longer screening intervals (every 5 years or more) might be feasible and safe.

UR - http://www.scopus.com/inward/record.url?scp=85039954887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039954887&partnerID=8YFLogxK

U2 - 10.7326/M17-1609

DO - 10.7326/M17-1609

M3 - Article

C2 - 29181509

AN - SCOPUS:85039954887

VL - 168

SP - 20

EP - 29

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -